Eli Lilly has agreed to acquire Ajax Therapeutics, a blood cancer drug developer, for an upfront cash payment plus milestone payments that could total up to $2.3 billion. The deal centers on AJ1-11095, an experimental therapy targeting myelofibrosis — a rare and serious chronic bone marrow disorder. The acquisition signals Lilly's intent to expand its oncology pipeline beyond its dominant GLP-1 franchise.
For Lilly shareholders, this deal adds a credible early-stage oncology asset without straining the balance sheet at a size that's material but not bet-the-company. Myelofibrosis is a high-value rare disease market with limited treatment options, meaning pricing power is strong if AJ1-11095 advances. The milestone structure also limits downside — Lilly only pays full price if the drug actually performs.
Ajax AJ1-11095 clinical trial updates (no fixed date — watch Lilly's pipeline disclosures). Lilly Q2 2025 earnings call: expected late July 2025. FDA rare disease designation announcements: rolling basis.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief